Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ZVSA
ZYVERSA THERAPEUTICS, INC.
OTC
$0.10
▲ UP 6.06% (0.01)

KEY STATISTICS

Market Cap$850.07 K
52w High$0.30
52w Low$0.08
Dividend Yield—
Frequency—
P/E-0.03
Volume504
Shares Out.8.10M

COMPANY

LEADERSHIP

Stephen C. Glover
CHIEF EXECUTIVE
Stephen C. Glover

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 11, 2022
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
6

UPCOMING EARNINGS

DateAug 31, 2026
DayMonday
Rev. Est.—
AUG
31
MON

SPLIT RECORD

DATETYPERATIO
2024-04-26Reverse1:10
2023-12-05Reverse1:35

PRICE

$0.10 ▲ UP 6.06% (+$0.01)
OVERLAYS
$0.10$0.11$0.11$0.119:30 AM10:01 AM10:33 AM11:04 AM11:35 AM12:07 PM12:38 PM0.10

About ZyVersa Therapeutics, Inc.

https://www.zyversa.com ↗

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company in Weston, Florida, developing treatments for renal and inflammatory diseases, including VAR 200 for kidney conditions and IC 100 as an inflammasome inhibitor.

INDUSTRY

Biotechnology

A PRODUCT ZYVERSA THERAPEUTICS, INC. IS KNOWN FOR

VAR 200
VAR 200

ZyVersa's leading Phase 2a injectable drug candidate targets renal diseases like diabetic kidney disease, FSGS, and Alport syndrome, representing the company's primary focus.

COMPETITORS

COMPETITOR
IONS COMPARE
NVS COMPARE
OMER COMPARE
TVTX COMPARE
VRTX COMPARE

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

SECTORS PEERS

PEERPRICE
INDP$1.14COMPARE
JSPR$0.70COMPARE
ONCO$0.61COMPARE
HEPA$0.10COMPARE
CDT$1.69COMPARE
ENVB$1.37COMPARE
XAGE$0.22COMPARE
SLXN$0.36COMPARE